ABIONYX Pharma Announces a Capital Increase

ABIONYX Pharma, a biopharmaceutical company based in Toulouse and Fullerton, has announced a capital increase of approximately €1.8 million. The transaction, which includes no preferential subscription rights, will finance its projects, particularly in the areas of sepsis and critical care.

The subscription price is set at €3.10 per share, representing a discount to the previous closing price. This fundraising is intended to strengthen the company's cash position until the end of 2026. The new shares issued will represent approximately 1.66% of the share capital.

Subscription commitments cover more than half of the issue, with a guaranteed investment reaching 800,000 euros, ensuring almost 100% of the planned subscription.